Roche Holding AG Total Current Liabilities 2010-2023 | RHHBY
Roche Holding AG total current liabilities from 2010 to 2023. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
- Roche Holding AG total current liabilities for the quarter ending December 31, 2023 were $27.651B, a 2.91% increase year-over-year.
- Roche Holding AG total current liabilities for 2023 were $27.651B, a 3.13% decline from 2022.
- Roche Holding AG total current liabilities for 2022 were $28.544B, a 32.09% decline from 2021.
- Roche Holding AG total current liabilities for 2021 were $42.031B, a 55.14% increase from 2020.
Roche Holding AG Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$27,651 |
| 2022 |
$28,544 |
| 2021 |
$42,031 |
| 2020 |
$27,093 |
| 2019 |
$24,276 |
| 2018 |
$23,549 |
| 2017 |
$22,521 |
| 2016 |
$22,946 |
| 2015 |
$24,735 |
| 2014 |
$25,287 |
| 2013 |
$17,013 |
| 2012 |
$21,565 |
| 2011 |
$18,355 |
| 2010 |
$14,394 |
| 2009 |
$20,381 |
Roche Holding AG Quarterly Total Current Liabilities
(Millions of US $) |
| 2023-12-31 |
$27,651 |
| 2022-12-31 |
$28,544 |
| 2022-06-30 |
$28,385 |
| 2021-12-31 |
$42,031 |
| 2021-06-30 |
$26,871 |
| 2020-12-31 |
$27,093 |
| 2020-06-30 |
$23,310 |
| 2019-12-31 |
$24,276 |
| 2019-06-30 |
$23,394 |
| 2018-12-31 |
$23,549 |
| 2018-06-30 |
$23,384 |
| 2017-12-31 |
$22,521 |
| 2017-06-30 |
$20,926 |
| 2016-12-31 |
$22,946 |
| 2016-06-30 |
$25,204 |
| 2015-12-31 |
$24,735 |
| 2015-06-30 |
$23,061 |
| 2014-12-31 |
$25,287 |
| 2014-06-30 |
$20,129 |
| 2013-12-31 |
$17,013 |
| 2013-06-30 |
$17,197 |
| 2012-12-31 |
$21,565 |
| 2012-06-30 |
$19,258 |
| 2011-12-31 |
$18,355 |
| 2011-06-30 |
$17,670 |
| 2010-12-31 |
$14,394 |
| 2010-06-30 |
$15,928 |
| 2009-12-31 |
$20,381 |
| 2009-06-30 |
$23,927 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$247.847B |
$65.370B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
